Reply to correspondence on "Genomic biomarkersto predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial"

被引：0
|
作者：
Kanzaki, Hiroaki [1 ,2 ]
Hoshida, Yujin [2 ]
机构：
[1] Chiba Univ, Grad Sch Med, Dept Gastroenterol, Chiba, Japan
[2] Univ Texas Southwestern Med Ctr, Dept Internal Med, Div Digest & Liver Dis, 5323 Harry Hines Blvd, Dallas, TX 75390 USA
来源：
CLINICAL AND MOLECULAR HEPATOLOGY | 2025年 / 31卷 / 01期
关键词：
Hepatocellular carcinoma; Immunotherapy; Predictive biomarker; Tumor immune microenvironment;
D O I：
10.3350/cmh.2024.0886
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页数：3
相关论文
共 18 条
  • [1] Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
    Yim, Sun Young
    Lee, Sung Hwan
    Baek, Seung-Woo
    Sohn, Bohwa
    Jeong, Yun Seong
    Kang, Sang-Hee
    Park, Kena
    Park, Hyewon
    Lee, Sunyoung S.
    Kaseb, Ahmed O.
    Park, Young Nyun
    Leem, Sun-Hee
    Curran, Michael A.
    Kim, Ji Hoon
    Lee, Ju-Seog
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [2] Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial"
    Lee, Sung Hwan
    Yim, Sun Young
    Kim, Ji Hoon
    Lee, Sunyoung S.
    Kaseb, Ahmed
    Wei, Peng
    Lee, Ju-Seog
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
  • [3] Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial"
    Yim, Sun Young
    Lee, Sung Hwan
    Kim, Ji Hoon
    Lee, Sunyoung S.
    Kaseb, Ahmed O.
    Lee, Ju-Seog
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
  • [4] Transcriptomic signature in advanced hepatocellular carcinoma tissue to predict combination immunotherapy response: Editorial on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial"
    Kanzaki, Hiroaki
    Hoshida, Yujin
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
  • [5] Personalized approaches to the treatment of hepatocellular carcinoma using immune checkpoint inhibitors: Editorial on "Genomic biomarkersto predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial"
    Nishida, Naoshi
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
  • [6] Characterization of response to atezolizumab plus bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
    Salem, Riad
    Li, Daneng
    Sommer, Nicolas
    Hernandez, Sairy
    Verret, Wendy
    Ding, Beiying
    Lencioni, Riccardo
    CANCER MEDICINE, 2021, 10 (16): : 5437 - 5447
  • [7] Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial
    Gao, Yuan
    Cheng, Ann-Lii
    Li, Lee X.
    Parent, Natalie
    Kichenadasse, Ganessan
    Karapetis, Christos S.
    Rowland, Andrew
    Hopkins, Ashley M.
    Sorich, Michael J.
    INTERNATIONAL JOURNAL OF CANCER, 2025,
  • [8] Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: Results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial
    Li, Daneng
    Toh, Han Chong
    Merle, Philippe
    Tsuchiya, Kaoru
    Hernandez, Sairy
    Verret, Wendy
    Nicholas, Alan
    Kudo, Masatoshi
    LIVER CANCER, 2022, 11 (06) : 558 - 571
  • [9] Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria
    Sho, Takuya
    Suda, Goki
    Ogawa, Koji
    Kimura, Megumi
    Kubo, Akinori
    Tokuchi, Yoshimasa
    Kitagataya, Takashi
    Maehara, Osamu
    Ohnishi, Shunsuke
    Shigesawa, Taku
    Nakamura, Akihisa
    Yamada, Ren
    Ohara, Masatsugu
    Kawagishi, Naoki
    Natsuizaka, Mitsuteru
    Nakai, Masato
    Morikawa, Kenichi
    Furuya, Ken
    Baba, Masaru
    Yamamoto, Yoshiya
    Suzuki, Kazuharu
    Izumi, Takaaki
    Meguro, Takashi
    Terashita, Katsumi
    Ito, Jun
    Miyagishima, Takuto
    Sakamoto, Naoya
    HEPATOLOGY RESEARCH, 2021, 51 (09) : 979 - 989
  • [10] Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150
    Finn, Richard S.
    Galle, Peter R.
    Ducreux, Michel
    Cheng, Ann-Lii
    Reilly, Norelle
    Nicholas, Alan
    Hernandez, Sairy
    Ma, Ning
    Merle, Philippe
    Salem, Riad
    Li, Daneng
    Breder, Valeriy
    LIVER CANCER, 2024, 13 (06) : 655 - 668
12